Virology News and Research

Latest Virology News and Research

Researchers explain how HSV dismantles host's defense systems

A viral infection is like an uninvited, tenacious houseguest in the cell, using a range of tricks to prevent its eviction. Researchers at the Salk Institute for Biological Studies have identified one of the key proteins allowing herpes simplex virus (HSV) DNA to fly under the radar of their hosts' involuntary hospitality.

21 Jan 2010

Study: PrEP treatment offers protection against HIV transmission in humanized mice

Systemic pre-exposure administration of antiretroviral drugs provides protection against intravenous and rectal transmission of HIV in mice with human immune systems, according to a new study published January 21, 2010 in the online journal PLoS ONE.

21 Jan 2010

Discovery of new class of compounds may help fight hepatitis C

Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.

21 Jan 2010

New class of HCV inhibitors discovered by Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "Identification of a Novel Class of HCV Inhibitors". Published in the January 20th edition of Science and Translational Medicine, the research validates a domain, termed 4BAH2, within the non-structural protein (NS4B) of the HCV genome, as essential for HCV replication and describes the development of a high-throughput screen leading to the identification of small molecule inhibitors of 4BAH2.

21 Jan 2010

Acyclovir does not reduce risk of HIV transmission for people infected with both HIV and HSV-2

A five-year international multi-center clinical trial has found that acyclovir, a drug widely used as a safe and effective treatment taken twice daily to suppress herpes simplex virus-2 (HSV-2), which is the most common cause of genital herpes, does not reduce the risk of HIV transmission when taken by people infected with both HIV and HSV-2.

21 Jan 2010

Circumcising newborn males cost effective strategy for HIV prevention, Rwandan study finds

Performing circumcisions on newborn boys to lower their risk for HIV infection later in life is more cost-effective than adolescent or adult circumcision, according to researchers at Rwanda's health ministry, Reuters reports.

21 Jan 2010

The Doctors Company becomes the first insurer to add CyberGuard for its members

The Doctors Company, the largest national insurer of physician and surgeon medical liability in the U.S., became the first insurer to add CyberGuard for its members, extending the industry’s most relentless medical liability insurance to cover an emerging threat to medical practices—privacy and data security.

20 Jan 2010

HPV vaccine will reduce number of cervical cancer cases in women under 30

The number of women under 30 diagnosed with cervical cancer will fall nearly two thirds by 2025, thanks to the HPV vaccine.

20 Jan 2010

Telaprevir effective in HCV patients

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that data from recent clinical trials suggest that Vertex/Johnson & Johnson/Mitsubishi Tanabe's telaprevir is efficacious in hepatitis C virus patients who have not responded to previous treatment with peg-IFN/ribavirin. In contrast, the efficacy of Merck's (formerly Schering-Plough) boceprevir in treatment nonresponders has yet to be proven.

20 Jan 2010

Scientists explore new ways to counteract viral infections

For the first time the research world has managed to measure the energy that is used when a virus infects a cell. The aim is to find a way to reduce the amount of energy inside the virus and thereby ultimately find a medicine that can counteract infections.

20 Jan 2010

Scientists discover Ebola's immune evasion strategies

A research team led by Gaya Amarasinghe, an assistant professor of biochemistry, biophysics and molecular biology, had previously solved the structure of a critical part of an Ebola protein known as VP35, which is involved in host immune suppression.

20 Jan 2010

U.S. gastroenterologists to treat hepatitis C patients with telaprevir

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that U.S. gastroenterologists will treat a larger proportion of treatment nonresponder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe's telaprevir than Merck's boceprevir.

20 Jan 2010

National Institutes of Mental Health awards $8M for HIV research

A multidisciplinary research team at the Johns Hopkins University School of Medicine has been awarded $8 million in funding by the National Institutes of Mental Health to develop methods to rid the body of HIV.

20 Jan 2010

Preliminary data from Phase 1 study of Sangamo BioSciences' SB-728-T announced

Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis."

20 Jan 2010

CytoDyn commences enrollment in Cytolin clinical trial

Following approval of the Institutional Review Board, CytoDyn, Inc. has discharged its duty to register a clinical trial of Cytolin®, the Company’s lead product, with the government’s website at www.clinicaltrials.gov, ID NCT01048372. The public has online access to this federal database, which describes the key elements of clinical trials and their status.

19 Jan 2010

California limits HMO wait times

The regulations by the California Department of Managed Health Care, in the works for much of the last decade, will require that patients be treated by HMO doctors within 10 business days of requesting an appointment, and by specialists within 15.

19 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

Mutagenic drugs designed to kill viruses may make them stronger, says research

As the flu season continues in full-swing, most people can appreciate the need for drugs that stop viruses after they take hold in the body. Despite this serious need for new drugs, a team of researchers from the University of Texas at Austin raise serious concerns about an emerging strategy for stopping viral infections.

18 Jan 2010

Missouri best in using federal aid to combat Medicaid fraud, other states fight over federal rules

The Kansas City Star reports that Missouri led the country in 2008 in efficiency in using federal dollars to combat Medicaid fraud. "The state recovered almost $29.8 million in 2008, the most recent year for which comparative data are available, while receiving about $1.6 million in federal Medicaid fraud grants. That equates to $18.81 recovered for every dollar received — 43 cents better than the next-best state" (Noble, 1/12).

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010